Pancreatic Cancer Research

ResearcherZhengzhou UniversityActive in the last 2 years

Suxia Luo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6805-7650; OpenAlex author ID A5075221223. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
8
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. Retraction of: Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. Co-author DOI 10.18632/aging.206242↗
  2. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report. Last author DOI 10.1097/cad.0000000000001173↗
  3. The Scavenger Receptor MARCO Expressed by Tumor-Associated Macrophages Are Highly Associated With Poor Pancreatic Cancer Prognosis. Last author DOI 10.3389/fonc.2021.771488↗
  4. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells. Last author PMID 26261532↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yanqiu Zhao · 1 shared paper, 2025 · strength 0.30
  2. Yu Mu · 1 shared paper, 2025 · strength 0.30
  3. Shuyi Li · 1 shared paper, 2022 · strength 0.19
  4. Bian Shi · 1 shared paper, 2021 · strength 0.14
  5. Tao Huang · 1 shared paper, 2021 · strength 0.14
  6. Yuechao Ding · 1 shared paper, 2015 · strength 0.06
  7. Bo Meng · 1 shared paper, 2015 · strength 0.06
  8. Chao Ma · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.